Her2

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Endometrial02 Phase 3 Trial of ENHERTU� Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer ... .

Edit

ENHERTU� Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 ...

Business Wire 22 Dec 2025

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU� Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer ... .

Edit

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer (Biovaxys Technology Corp)

Public Technologies 17 Dec 2025

). The text version of this document is not available ... Disclaimer ... (noodl. 128492947) .

Edit

Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients ...

Rio Grande Sun 16 Dec 2025

FDA expands labels for Roche's PATHWAY HER2 (4B5) ...

Edit

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer (Form 6-K) (AstraZeneca plc)

Public Technologies 16 Dec 2025

With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in patients with HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer and are exploring its potential in ...

Edit

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers (Form 8-K) (Abpro Holdings Inc)

Public Technologies 15 Dec 2025

Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema.

Edit

Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU

PR Newswire 15 Dec 2025

Roche's PATHWAY HER2 (4B5) test is the only test approved to identify all levels of HER2 expression ... Until now, Roche's PATHWAY HER2 (4B5) test had been approved for identifying mBC patients with HER2-low and HER2-ultralow expression.

Edit

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer (AstraZeneca plc)

Public Technologies 15 Dec 2025

With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in patients with HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer and are exploring its potential in ...

Edit

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer (Daiichi Sankyo Co Ltd)

Public Technologies 15 Dec 2025

as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ... ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE.

Edit

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer (AstraZeneca Pharmaceuticals LP)

Public Technologies 15 Dec 2025

HER2-Positive, HER2-Low, and HER2-Ultralow Metastatic Breast Cancer, HER2-Mutant NSCLC, and Solid Tumors (Including IHC 3+) (5.4 mg/kg) ... HER2-Positive, HER2-Low, and HER2-Ultralow Metastatic Breast ...

Edit

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

PR Newswire 12 Dec 2025

Of those diagnosed, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for 70-75% of breast cancer, representing the largest subtype.

Podcasts:

Latest News for: her2

ENHERTU® Approved in China as First HER2 Directed Medicine for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies (Daiichi Sankyo Co Ltd)

Lunit SCOPE Demonstrates High Concordance with Pathologists in HER2 Interpretation for Advanced Biliary Tract Cancer

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 ...

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing ...

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU� Initiated as Adjuvant Therapy in Patients with HER2 Expressing ...

ENHERTU� Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 ...

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer (Biovaxys Technology Corp)

Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients ...

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer (Form 6-K) (AstraZeneca plc)

Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers (Form 8-K) (Abpro Holdings Inc)

Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer (AstraZeneca plc)

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer (Daiichi Sankyo Co Ltd)

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer (AstraZeneca Pharmaceuticals LP)

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Article Search

EXPLORE WN.com